NEW YORK (360Dx) – NanoMolecularDX on Wednesday said it had closed $1 million in seed funding through a private placement.

The offering was for preferred stock in the Lee, Massachusetts-based developer of in vitro diagnostic and research-use only tests. Proceeds will go toward commercialization of its diagnostics, the development of additional diagnostic clinical trials, and the expansion of its operations, it said, adding it is executing a commercialization strategy for its three proprietary tests — for fatty acid synthase, CA-IX, and HER-2/neu.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.